首页> 外国专利> T CELL RECEPTOR SPECIFIC FOR WILMS TUMOUR ANTIGEN

T CELL RECEPTOR SPECIFIC FOR WILMS TUMOUR ANTIGEN

机译:T细胞受体特定于威尔姆斯肿瘤抗原

摘要

A T cell receptor molecule (TCR) containing an alpha chain portion and a beta chain portion wherein the alpha chain portion contains three complementarity determining regions (CDRs): CDR1±: SSYSPS CDR2±: YTSAATL CDR3±: VVSPFSGGGADGLT or comprising or consisting of SPFSGGGADGLT and the beta chain portion contains three complementarity determining regions (CDRs): CDR11²: DFQATT CDR2²: SNEGSKA CDR3²: comprising SARDGGEG or comprising or consisting of RDGGEGSETQY, or wherein up to three amino acid residues in one or more CDRs are replaced by another amino acid residue. The invention also includes polynucleotides encoding the TCR molecules, and host cells containing the said polynucleotides. Patient derived T cells may have the polynucleotides encoding the TCR molecules introduced therein, and the engineered T cells may be introduced into the patient in order to combat a WT1-expressing malignancy.
机译:T细胞受体分子(TCR),包含α链部分和β链部分,其中α链部分包含三个互补决定区(CDR):CDR1±:SSYSPSCDR2±:YTSAATLCDR3±:VVSPFSGGGGGADGLT或包含SPFSGGGADGLT或由其组成β链部分包含三个互补决定区(CDR):CDR11²:DFQATTCDR2²:SNEGSKACDR3 2:包含SARDGGEG或包含RDGGEGSETQY或由RDGGEGSETQY组成,或其中一个或多个CDR中的至多三个氨基酸残基被另一氨基酸残基取代。本发明还包括编码TCR分子的多核苷酸,和包含所述多核苷酸的宿主细胞。患者来源的T细胞可以具有引入其中的编码TCR分子的多核苷酸,并且工程化的T细胞可以被引入患者中以对抗表达WT1的恶性肿瘤。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号